iodixanol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
iodine-containing contrast media 3302 92339-11-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • iodixanol
  • visipaque
dimeric contrast media; structure given in first source
  • Molecular weight: 1550.19
  • Formula: C35H44I6N6O15
  • CLOGP: -4.28
  • LIPINSKI: 3
  • HAC: 21
  • HDO: 13
  • TPSA: 339.09
  • ALOGS: -3.92
  • ROTB: 22

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.44 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.10 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
March 22, 1996 FDA GE HEALTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pruritus 259.24 38.75 188 3127 541337 90083795
Contrast media allergy 177.70 38.75 37 3278 3044 90622088
Erythema 142.68 38.75 94 3221 229152 90395980
Acute generalised exanthematous pustulosis 140.33 38.75 41 3274 13662 90611470
Urticaria 125.08 38.75 98 3217 312636 90312496
Contrast encephalopathy 100.60 38.75 15 3300 170 90624962
Rash maculo-papular 93.13 38.75 40 3275 40893 90584239
Anaphylactic reaction 85.47 38.75 48 3267 87476 90537656
Rash 73.21 38.75 115 3200 795985 89829147
Swelling face 72.39 38.75 42 3273 81310 90543822
Contrast media reaction 71.97 38.75 15 3300 1236 90623896
Schizencephaly 70.39 38.75 12 3303 331 90624801
Cerebral haemorrhage foetal 70.22 38.75 12 3303 336 90624796
Anaphylactic shock 68.96 38.75 30 3285 31587 90593545
Eyelid oedema 57.66 38.75 20 3295 11514 90613618
Acute kidney injury 56.79 38.75 64 3251 320323 90304809
Anaphylactoid shock 54.40 38.75 10 3305 428 90624704
Rash erythematous 53.65 38.75 32 3283 65072 90560060
Anaphylactoid reaction 52.99 38.75 15 3300 4453 90620679
Rash pustular 52.29 38.75 17 3298 8032 90617100
Flushing 51.72 38.75 35 3280 88456 90536676
Dyspnoea 50.87 38.75 104 3211 880851 89744281
Drug reaction with eosinophilia and systemic symptoms 45.94 38.75 25 3290 42733 90582399
Lactic acidosis 44.71 38.75 26 3289 50437 90574695
Hyperkalaemia 43.54 38.75 28 3287 64936 90560196
Henoch-Schonlein purpura 41.32 38.75 10 3305 1617 90623515

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Contrast media allergy 376.92 36.73 64 3502 723 42617046
Contrast media reaction 277.24 36.73 52 3514 1064 42616705
Pruritus 270.24 36.73 177 3389 188594 42429175
Erythema 208.19 36.73 123 3443 108670 42509099
Urticaria 180.00 36.73 98 3468 73938 42543831
Rash 155.62 36.73 150 3416 276804 42340965
Anaphylactic reaction 104.80 36.73 57 3509 42686 42575083
Contrast encephalopathy 103.62 36.73 17 3549 152 42617617
Rash maculo-papular 91.87 36.73 50 3516 37453 42580316
Acute generalised exanthematous pustulosis 82.77 36.73 30 3536 8565 42609204
Eosinophilia 72.70 36.73 41 3525 32858 42584911
Acute kidney injury 71.20 36.73 117 3449 367220 42250549
Swelling face 70.97 36.73 38 3528 27516 42590253
Dysphoria 64.94 36.73 19 3547 2761 42615008
Rash scarlatiniform 63.86 36.73 11 3555 135 42617634
Rash pruritic 51.21 36.73 33 3533 33570 42584199
Flushing 50.68 36.73 34 3532 36994 42580775
Chills 48.72 36.73 49 3517 94017 42523752
Eyelid oedema 47.89 36.73 18 3548 5677 42612092
Angioedema 46.47 36.73 34 3532 42443 42575326
Hypotension 45.63 36.73 79 3487 257552 42360217
Nephropathy toxic 45.53 36.73 24 3542 16814 42600955
Face oedema 44.26 36.73 22 3544 13644 42604125
Skin tightness 42.50 36.73 13 3553 2197 42615572
Dermatitis allergic 40.95 36.73 18 3548 8465 42609304
Anaphylactoid reaction 38.66 36.73 13 3553 2970 42614799
Rash erythematous 38.09 36.73 27 3539 32064 42585705

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pruritus 505.18 34.72 357 6500 581203 110001239
Contrast media allergy 498.00 34.72 97 6760 3326 110579116
Contrast media reaction 336.77 34.72 66 6791 2332 110580110
Erythema 328.36 34.72 211 6646 291236 110291206
Urticaria 257.28 34.72 188 6669 318669 110263773
Acute generalised exanthematous pustulosis 212.40 34.72 71 6786 21593 110560849
Rash 208.25 34.72 254 6603 820710 109761732
Anaphylactic reaction 185.84 34.72 105 6752 114195 110468247
Contrast encephalopathy 177.28 34.72 29 6828 353 110582089
Rash maculo-papular 170.88 34.72 86 6771 74136 110508306
Swelling face 131.84 34.72 78 6779 92243 110490199
Acute kidney injury 129.72 34.72 177 6680 635253 109947189
Eosinophilia 107.15 34.72 58 6799 57878 110524564
Dysphoria 104.44 34.72 31 6826 6397 110576045
Anaphylactic shock 96.42 34.72 52 6805 51494 110530948
Flushing 96.13 34.72 67 6790 104669 110477773
Eyelid oedema 96.03 34.72 36 6821 15226 110567216
Rash erythematous 83.73 34.72 56 6801 81776 110500666
Anaphylactoid reaction 81.54 34.72 26 6831 6800 110575642
Angioedema 81.13 34.72 59 6798 98441 110484001
Drug reaction with eosinophilia and systemic symptoms 76.44 34.72 53 6804 82042 110500400
Hypotension 72.52 34.72 122 6735 523727 110058715
Dyspnoea 72.16 34.72 189 6668 1106683 109475759
Rash pruritic 70.18 34.72 54 6803 98015 110484427
Anaphylactoid shock 67.62 34.72 15 6842 971 110581471
Chills 66.59 34.72 70 6787 190510 110391932
Face oedema 66.04 34.72 35 6822 33434 110549008
Rash scarlatiniform 63.22 34.72 12 6845 356 110582086
Dermatitis allergic 61.42 34.72 29 6828 21695 110560747
Skin tightness 61.40 34.72 20 6837 5593 110576849
Nephropathy toxic 60.70 34.72 31 6826 27447 110554995
Toxic skin eruption 57.78 34.72 30 6827 27485 110554957
Rash pustular 55.21 34.72 23 6834 12806 110569636
Drug ineffective 54.05 34.72 14 6843 1520526 109061916
Henoch-Schonlein purpura 52.35 34.72 16 6841 3641 110578801
Throat irritation 46.17 34.72 33 6824 53519 110528923
Chest discomfort 43.93 34.72 54 6803 173794 110408648
Eye swelling 42.15 34.72 26 6831 33022 110549420
Cyanosis 42.06 34.72 25 6832 29716 110552726
Throat tightness 41.83 34.72 26 6831 33463 110548979
Shock 41.61 34.72 31 6826 53557 110528885
Skin induration 41.43 34.72 14 6843 4381 110578061
Cold sweat 40.54 34.72 22 6835 22009 110560433
Fatigue 39.83 34.72 13 6844 1215945 109366497
Blood pressure decreased 37.90 34.72 41 6816 115050 110467392
Cardiac arrest 35.71 34.72 52 6805 196701 110385741
Iodine overload 35.60 34.72 5 6852 19 110582423
Nephropathy 35.08 34.72 17 6840 13450 110568992

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V08AB09 VARIOUS
CONTRAST MEDIA
X-RAY CONTRAST MEDIA, IODINATED
Watersoluble, nephrotropic, low osmolar X-ray contrast media
FDA MoA N0000010258 X-Ray Contrast Activity
MeSH PA D003287 Contrast Media
MeSH PA D064907 Diagnostic Uses of Chemicals
FDA EPC N0000180185 Radiographic Contrast Agent
CHEBI has role CHEBI:37338 radioopaque medium
CHEBI has role CHEBI:231911 renoprotective agent

Related Drugs by ATC class:

V08AB Watersoluble, nephrotropic, low osmolar X-ray contrast media 11 drugs
iobitridoliohexoliomeproliopamidoliopentoliopromideiotrolanioversolioxaglic acidioxilanmetrizamide

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.43 acidic
pKa2 10.85 acidic
pKa3 11.21 acidic
pKa4 11.63 acidic
pKa5 12.19 acidic
pKa6 13.65 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4020982 VUID
N0000148453 NUI
D01474 KEGG_DRUG
4020982 VANDF
C0063757 UMLSCUI
CHEBI:31705 CHEBI
CHEMBL1200507 ChEMBL_ID
DB01249 DRUGBANK_ID
C044834 MESH_SUPPLEMENTAL_RECORD_UI
5692 INN_ID
HW8W27HTXX UNII
3724 PUBCHEM_CID
27729 RXNORM
11441 MMSL
360836 MMSL
4902 MMSL
d04016 MMSL
006060 NDDF
353962003 SNOMEDCT_US
395750001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Visipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-2222 INJECTION, SOLUTION 270 mg INTRAVASCULAR NDA 28 sections
Visipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-2222 INJECTION, SOLUTION 270 mg INTRAVASCULAR NDA 28 sections
Visipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-2222 INJECTION, SOLUTION 270 mg INTRAVASCULAR NDA 28 sections
Visipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-2223 INJECTION, SOLUTION 320 mg INTRAVASCULAR NDA 28 sections
Visipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-2223 INJECTION, SOLUTION 320 mg INTRAVASCULAR NDA 28 sections
Visipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-2223 INJECTION, SOLUTION 320 mg INTRAVASCULAR NDA 28 sections
Visipaque HUMAN PRESCRIPTION DRUG LABEL 1 0407-2223 INJECTION, SOLUTION 320 mg INTRAVASCULAR NDA 28 sections
Iodixanol HUMAN PRESCRIPTION DRUG LABEL 1 65219-381 INJECTION, SOLUTION 270 mg INTRAVASCULAR ANDA 28 sections
Iodixanol HUMAN PRESCRIPTION DRUG LABEL 1 65219-383 INJECTION, SOLUTION 320 mg INTRAVASCULAR ANDA 28 sections